Ray Dalio’s Omega Healthcare OHI Stock Holding History

Ray Dalio’s Portfolio OHI Stock Details OHI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-18,216	Closed	-$769K	–	1143
2025 Q3	$769K	Sell	18,216 -1,423	-7%	-$57.4K	﹤0.01%	877
2025 Q2	$720K	Buy	19,639 +12,106	+161%	+$449K	﹤0.01%	497
2025 Q1	$287K	Buy	+7,533	New	+$280K	﹤0.01%	615
2021 Q2	–	Sell	-10,846	Closed	-$397K	–	751
2021 Q1	$397K	Buy	+10,846	New	+$399K	﹤0.01%	395

Other funds holding OHI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cohen & Steers New York $57.6B AUM 8.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ray Dalio's OHI Position: Q4 2025 in Review

Ray Dalio sold out of Omega Healthcare (OHI) in Q4 2025, closing a stake of 18,216 shares — an estimated $769K sold.

Ray Dalio first reported a position in OHI in Q1 2021 and held it in 4 quarters. The position peaked at $769K in Q3 2025. 723 funds tracked by Wall St. Rank hold OHI as of Q4 2025.

Ray Dalio reported no remaining Omega Healthcare position as of Q4 2025 after selling out during the quarter.
Ray Dalio sold 18,216 Omega Healthcare shares in Q4 2025, an estimated $769K.
Ray Dalio first reported a position in Omega Healthcare in Q1 2021 and held it in 4 quarters.
Ray Dalio's Omega Healthcare position peaked at $769K in Q3 2025.
723 funds tracked by Wall St. Rank held Omega Healthcare as of Q4 2025.

Based on Bridgewater Associates's 13F filing for Q4 2025, filed 13 Feb 2026.